A 2-Dose AERAS-402 Regimen Boosts CD8+ Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients

A 2-Dose AERAS-402 Regimen Boosts CD8+ Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients

Despite the widespread use of BCG, tuberculosis (TB) remains a global threat. Existing vaccine candidates in clinical trials are designed to replace or boost BCG which does not provide satisfying long-term protection. AERAS-402 is a replication-deficient Ad35 vaccine encoding a fusion protein of the...

Full description

Bibliographic Details
Main Authors: Dhanasekaran Sivakumaran, Gretta Blatner, Rasmus Bakken, David Hokey, Christian Ritz, Synne Jenum, Harleen M. S. Grewal
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Immunology
Subjects:
TB vaccine
tuberculosis
T-cell responses
transcriptional profiling
AERAS-402
Phase 1 trial
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.673532/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.673532/full

Similar Items